New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry.
作者信息
Ungaro Ryan C, Agrawal Manasi, Brenner Erica J, Zhang Xian, Colombel Jean-Frederic, Kappelman Michael D, Reinisch Walter
机构信息
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
出版信息
Inflamm Bowel Dis. 2022 Feb 1;28(2):314-317. doi: 10.1093/ibd/izab184.
Abstract
摘要
相似文献
1
New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry.新型胃肠道症状在患有新冠肺炎的炎症性肠病患者中很常见：来自一个国际登记处的数据。
Inflamm Bowel Dis. 2022 Feb 1;28(2):314-317. doi: 10.1093/ibd/izab184.
2
COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist.新型冠状病毒肺炎与胃肠道疾病：对胃肠病学家的启示。
Dig Dis. 2021;39(2):119-139. doi: 10.1159/000512152. Epub 2020 Oct 9.
3
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry.药物对炎症性肠病患者新冠病毒病结局的影响：来自一项国际登记处的6000多名患者的分析
Gastroenterology. 2022 Jan;162(1):316-319.e5. doi: 10.1053/j.gastro.2021.09.011. Epub 2021 Sep 14.
4
Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators.新型冠状病毒肺炎对炎症性肠病临床试验招募的影响：一项针对主要研究者的全球调查
Inflamm Bowel Dis. 2021 Jul 27;27(8):e98. doi: 10.1093/ibd/izab111.
5
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.维得利珠单抗对 SECURE-IBD 注册研究中成年 IBD 患者 COVID-19 结局的影响。
J Crohns Colitis. 2021 Nov 8;15(11):1877-1884. doi: 10.1093/ecco-jcc/jjab071.
6
[The gastrointestinal effects of COVID–19 infection during childhood and among the children affected with inflammatory bowel disease].[儿童期及炎症性肠病患儿中新型冠状病毒肺炎感染的胃肠道影响]
Orv Hetil. 2022 Feb 6;163(6):214-221. doi: 10.1556/650.2022.32443.
7
GI-COVID: Are There COVID-19 Patients with Primary Gastrointestinal SARS-CoV-2 Infection and Symptoms?胃肠道新冠病毒感染：是否存在以胃肠道为主要感染部位并出现症状的新冠病毒肺炎患者？
Dig Dis Sci. 2021 Oct;66(10):3228-3230. doi: 10.1007/s10620-020-06767-5. Epub 2021 Jan 11.
8
COVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020.2020年4月1日至7月31日美国患有炎症性肠病的医疗保险受益人的COVID-19住院情况
Inflamm Bowel Dis. 2021 Jun 15;27(7):1166-1169. doi: 10.1093/ibd/izab041.
9
Factors Associated With Severe Gastrointestinal Diagnoses in Children With SARS-CoV-2 Infection or Multisystem Inflammatory Syndrome.与感染SARS-CoV-2或多系统炎症综合征的儿童严重胃肠道诊断相关的因素
JAMA Netw Open. 2021 Dec 1;4(12):e2139974. doi: 10.1001/jamanetworkopen.2021.39974.
10
GI symptoms and fever increase the risk of severe illness and death in patients with COVID-19.胃肠道症状和发热会增加新冠肺炎患者出现重症和死亡的风险。
Gut. 2021 Feb;70(2):442-444. doi: 10.1136/gutjnl-2020-321751. Epub 2020 Jun 30.
引用本文的文献
1
Long-Term Sequelae of SARS-CoV-2 Infection in Patients with Inflammatory Bowel Diseases Compared to Relatives with SARS-CoV-2 Infection without Inflammatory Bowel Disease and Inflammatory Bowel Disease Patients without SARS-CoV-2: Results of a Retrospective Case-Control Study.炎症性肠病患者感染新冠病毒的长期后遗症与无炎症性肠病的新冠病毒感染亲属及未感染新冠病毒的炎症性肠病患者的比较：一项回顾性病例对照研究的结果
Visc Med. 2025 Feb;41(1):21-31. doi: 10.1159/000541602. Epub 2024 Oct 29.
2
Inflammatory bowel diseases and the clinical course of coronavirus disease 2019 - a Polish single-centre experience from the pre-vaccine era.炎症性肠病与2019冠状病毒病的临床病程——波兰疫苗接种前时代的单中心经验
Prz Gastroenterol. 2023;18(4):409-415. doi: 10.5114/pg.2023.133479. Epub 2023 Dec 8.
3
The association of three vaccination doses with reduced gastrointestinal symptoms after severe acute respiratory syndrome coronavirus 2 infections in patients with inflammatory bowel disease.炎症性肠病患者感染严重急性呼吸综合征冠状病毒2后，三剂疫苗接种与胃肠道症状减轻之间的关联。
Front Med (Lausanne). 2024 Mar 18;11:1377926. doi: 10.3389/fmed.2024.1377926. eCollection 2024.
4
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.新型冠状病毒肺炎与炎症性肠病实用最新进展：新型冠状病毒肺炎疾病风险及疫苗安全性与有效性
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
5
Impact of the first wave of COVID-19 on Crohn's disease after the end of "zero-COVID" policy in China.中国“零新冠”政策结束后，首波 COVID-19 对克罗恩病的影响。
Front Public Health. 2023 Jul 13;11:1186275. doi: 10.3389/fpubh.2023.1186275. eCollection 2023.
6
Potential value of neuroimmunotherapy for COVID-19: efficacies and mechanisms of vagus nerve stimulation, electroacupuncture, and cholinergic drugs.神经免疫疗法治疗 COVID-19 的潜在价值：迷走神经刺激、电针和胆碱能药物的疗效和作用机制。
Front Immunol. 2023 Jul 5;14:1197467. doi: 10.3389/fimmu.2023.1197467. eCollection 2023.
7
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对接受生物治疗药物治疗的炎症性肠病患者病程的影响：一项病例对照研究。
Biomedicines. 2022 Apr 3;10(4):843. doi: 10.3390/biomedicines10040843.
Zotero 插件